Evidence map›Paper›PMID 40448502›Full record

ArticleNucleic acids research2025

Screening of metallohelices for enantioselective targeting SARS-CoV-2 RNA G-quadruplex.

Yue Sun, Chuanqi Zhao, Yan Liu, Yibo Wang, Cheng Zhang, Jie Yang, Geng Qin, Hualong Song, Miles Postings, Peter Scott and 2 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. G-Quadruplexes: Structural Diversity and Emerging Roles in Biomolecular Condensation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yue SunLaboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, P. R. China.
Chuanqi ZhaoLaboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, P. R. China.
Yan LiuChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, Jilin 130122, P. R. China.
Yibo WangLaboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, P. R. China.
Cheng ZhangChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, Jilin 130122, P. R. China.
Jie YangLaboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, P. R. China.
Geng QinLaboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, P. R. China.
Hualong SongDepartment of Chemistry, University of Warwick, Coventry, CV4 7AL, UK.
Miles PostingsDepartment of Chemistry, University of Warwick, Coventry, CV4 7AL, UK.
Peter ScottDepartment of Chemistry, University of Warwick, Coventry, CV4 7AL, UK.
Jinsong RenLaboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, P. R. China.ORCID 0000-0002-7506-627X
Xiaogang QuLaboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin 130022, P. R. China.ORCID 0000-0003-2868-3205

Funding

National Key R&D Program of China 2019YFA0709202National Key R&D Program of China 2021YFF1200700National Natural Science Foundation of China 22122704National Natural Science Foundation of China 22237006National Natural Science Foundation of China 22377120National Natural Science Foundation of China 22437006National Natural Science Foundation of China T2495262
6 · The paper itself

Abstract

The emergence of numerous variants of SARS-CoV-2 still presents the major challenges in the fight against this disease by reducing the efficacy of vaccines and drugs. RNA G-quadruplexes (G4s) in the SARS-CoV-2 genome are highly conserved and have thus been spotlighted as a promising therapeutic target to combat a wider range of variants. However, very few RNA G4 specific compounds have been reported. Here, a small library of 64 chiral metallohelices has been constructed for screening SARS-CoV-2 G4-specific binders. After screening, we found that one pair of the enantiomers showed the best enantioselectivity. The Λ enantiomer can strongly stabilize SARS-CoV-2 G4s, inhibit the expression of virus protein, and reduce the SARS-CoV-2 RNA copies and viral titers in Vero E6 cells. In contrast, the Δ enantiomer has much weaker effects than the Λ enantiomer under the same experimental conditions, showing an obvious enantioselectivity. Further studies indicate that the Λ enantiomer prefers binding to SARS-CoV-2 G4s rather than binding to the single/double-stranded DNA and commonly reported human DNA G4s, indicating its selectivity to RNA G4s. This work provides the first example for enantioselectively targeting SARS-CoV-2 G4s, and will promote developing drug candidates for targeting virus G4s.

Indexed as

Antiviral AgentsG-QuadruplexesRNA, ViralSARS-CoV-2AnimalsChlorocebus aethiopsCOVID-19COVID-19 Drug TreatmentHumansStereoisomerismVero CellsAntiviral AgentsRNA, Viral

Identifiers

PMID40448502
PMCPMC12125542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.